Local and targeted drug delivery for bone regeneration

Local and targeted drug delivery for bone regeneration Available online at www.sciencedirect.com ScienceDirect 1,2 1,2,3 Maureen R Newman and Danielle SW Benoit While experimental bone regeneration approaches commonly different levels of success clinically, there are still signifi- employ cells, technological hurdles prevent translation of these cant technological challenges. therapies. Alternatively, emulating the spatiotemporal cascade of endogenous factors through controlled drug delivery may To achieve translation of cell-based therapies, there are provide superior bone regenerative approaches. Surgically many hurdles to overcome. For bone regeneration, mesen- placed drug depots have clinical indications. Additionally, chymal stem cells (MSCs) are commonly used, as they can noninvasive systemic delivery can be used as needed for differentiate to cells required for bone healing (osteoblasts poorly healing bone injuries. However, a major hurdle for and chondrocytes). However, other cells (e.g., inflamma- systemic delivery is poor bone biodistribution of drugs. Thus, tory cells, endothelial cells) that play important roles in peptides, aptamers, and phosphate-rich compounds with bone regeneration may also be included. A challenge to the specificity toward proteins, cells, and molecules within the use of any cell type is assurance of cellular uniformity. With regenerative bone microenvironment may enable the design of MSCs as an example, the International Society for Cellular targeted carriers with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Biotechnology Elsevier

Local and targeted drug delivery for bone regeneration

Loading next page...
 
/lp/elsevier/local-and-targeted-drug-delivery-for-bone-regeneration-qOcbyti0oW
Publisher
Elsevier
Copyright
Copyright © 2016 Elsevier Ltd
ISSN
0958-1669
D.O.I.
10.1016/j.copbio.2016.02.029
Publisher site
See Article on Publisher Site

Abstract

Available online at www.sciencedirect.com ScienceDirect 1,2 1,2,3 Maureen R Newman and Danielle SW Benoit While experimental bone regeneration approaches commonly different levels of success clinically, there are still signifi- employ cells, technological hurdles prevent translation of these cant technological challenges. therapies. Alternatively, emulating the spatiotemporal cascade of endogenous factors through controlled drug delivery may To achieve translation of cell-based therapies, there are provide superior bone regenerative approaches. Surgically many hurdles to overcome. For bone regeneration, mesen- placed drug depots have clinical indications. Additionally, chymal stem cells (MSCs) are commonly used, as they can noninvasive systemic delivery can be used as needed for differentiate to cells required for bone healing (osteoblasts poorly healing bone injuries. However, a major hurdle for and chondrocytes). However, other cells (e.g., inflamma- systemic delivery is poor bone biodistribution of drugs. Thus, tory cells, endothelial cells) that play important roles in peptides, aptamers, and phosphate-rich compounds with bone regeneration may also be included. A challenge to the specificity toward proteins, cells, and molecules within the use of any cell type is assurance of cellular uniformity. With regenerative bone microenvironment may enable the design of MSCs as an example, the International Society for Cellular targeted carriers with

Journal

Current Opinion in BiotechnologyElsevier

Published: Aug 1, 2016

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off